

## **Zydus Cadila registers 39% increase in Net Profit in Q2**

---

*Ahmedabad, 27 October 2009*

For the second quarter ended September 30, 2009, Zydus Cadila's total income from operations was up by 28 % y-y to Rs. 9458 mn from Rs. 7409 mn, on a consolidated basis. EBIDT was up by 35 % y-y to Rs. 2057 mn from Rs. 1525 mn. Net profit was up by 39 % to Rs. 1319 mn from Rs. 949 mn last year.

During the quarter, the company's revenues were buoyed by 46% growth in the global formulations business driven by 101% y-y growth in the US business. The wellness business posted a growth of 37 % and the API exports registered a robust growth of 44% in the same period.

Domestic formulations business posted a growth of 10% with the launch of 14 new products, including line extensions, of which three products - Nucoxia MR 8 in the pain management segment, Pazubid 300 in the anti-infectives segment and Venz OD in the CNS segment, were the first to be launched in India.

Making rapid strides in its research programme, the company's collaborative research programme with Karo Bio generated a series of novel dissociated non-steroidal glucocorticoid agonist lead compounds. Among other key research milestones reached during the quarter, the group commenced the Phase III clinical trials for ZYH1, the lead molecule for dyslipidemia, and also filed the US IND for ZYD1, a novel candidate in the class of anti-diabetic agents.

Strengthening its regulatory pipeline the company, during the quarter, filed 3 DMFs with the USFDA, taking the cumulative filings to 82 DMFs. The company also filed 2 ANDAs and received 2 approvals, taking the cumulative number of filings to 95 and the total number of approvals to 50. Additionally, in the same period, the company filed 4 new product dossiers for the EU market, taking the cumulative filings to 60. The company has so far received 32 approvals for the EU market.

\*\*\*